Reuters logo
BRIEF-Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Active Psoriatic Arthritis
December 1, 2017 / 10:16 PM / in 9 days

BRIEF-Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Active Psoriatic Arthritis

Dec 1 (Reuters) - Eli Lilly And Co:

* LILLY‘S TALTZ® (IXEKIZUMAB) RECEIVES U.S. FDA APPROVAL FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below